{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:44:05Z","timestamp":1789811045483,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":2877,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13311-015-0369-3","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T11:04:41Z","timestamp":1436871881000},"page":"887-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis"],"prefix":"10.1016","volume":"12","author":[{"given":"Reza","family":"Boostani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samane Sadat","family":"Hosseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shoeibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahare","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Etemadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faeze","family":"Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Valizade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Abdolrahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0369-3_bib1","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/v2092037","article-title":"Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis","volume":"2","author":"Kannian","year":"2010","journal-title":"Viruses"},{"key":"10.1007\/s13311-015-0369-3_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1743-422X-9-71","article-title":"Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain","volume":"9","author":"Trevino","year":"2012","journal-title":"Virol J"},{"key":"10.1007\/s13311-015-0369-3_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","article-title":"High prevalence of HTLV-1 infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey","volume":"52","author":"Rafatpanah","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1007\/s13311-015-0369-3_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.acra.2012.03.020","article-title":"CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia","volume":"19","author":"Yamashiro","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1007\/s13311-015-0369-3_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1007\/s13311-015-0369-3_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/aid.2011.0248","article-title":"Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis","volume":"28","author":"Azarpazhooh","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1007\/s13311-015-0369-3_bib7","first-page":"428","article-title":"Khorasan disease: prevalence of HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in west Azarbaijan from 2004 to 2007","volume":"13","author":"Boostani","year":"2011","journal-title":"Iran Red Crescent Medical J"},{"key":"10.1007\/s13311-015-0369-3_bib8","first-page":"225","article-title":"Population-based seroprevalence of HTLV-1 infection in Golestan Province, South East of Caspian Sea, Iran","volume":"16","author":"Kalavi","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib9","first-page":"179","article-title":"Human T lymphotropic virus type I (HTLV-1) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell leukemia\/lymphoma (ATL)","volume":"16","author":"Ahmadi Ghezeldasht","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib10","first-page":"202","article-title":"\u201cHTLV-1 Infection\u201d twenty-year research in neurology department of Mashhad University of Medical Sciences","volume":"16","author":"Shoeibi","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib11","first-page":"217","article-title":"Human T lymphotropic virus type I (HTLV-1) is a risk factor for coronary artery disease","volume":"16","author":"Farid Hosseni","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.2741\/3300","article-title":"Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease","volume":"14","author":"Lepoutre","year":"2009","journal-title":"Front Biosci"},{"key":"10.1007\/s13311-015-0369-3_bib13","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.4049\/jimmunol.178.9.5966","article-title":"Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs","volume":"178","author":"Kubota","year":"2007","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0369-3_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1099\/0022-1317-83-3-641","article-title":"Presentation of a new H-2D(k)-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin","volume":"83","author":"Lomas","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1007\/s13311-015-0369-3_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1590\/S0074-02762006000300008","article-title":"Lack of tax diversity for tropical spastic paraparesis\/human T-cell lymphotropic virus type 1 (HTLV-1) associated myelopathy development in HTLV-1-infected subjects in Sao Paulo, Brazil","volume":"101","author":"Casseb","year":"2006","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1007\/s13311-015-0369-3_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fmicb.2012.00247","article-title":"HBZ and its roles in HTLV-1 oncogenesis","volume":"3","author":"Zhao","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1007\/s13311-015-0369-3_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1742-4690-6-71","article-title":"The HBZ gene, a key player in HTLV-1 pathogenesis","volume":"6","author":"Matsuoka","year":"2009","journal-title":"Retrovirology"},{"key":"10.1007\/s13311-015-0369-3_bib18","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2008-06-161729","article-title":"Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB","volume":"113","author":"Zhao","year":"2009","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0369-3_bib19","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1182\/blood-2010-11-321364","article-title":"Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM\/TSP T lymphocytes","volume":"118","author":"Belrose","year":"2011","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0369-3_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-4690-10-91","article-title":"The combination of arsenic, interferon-alpha, and zidovudine restores an \u201cimmunocompetent-like\u201d cytokine expression profile in patients with adult T-cell leukemia lymphoma","volume":"10","author":"Kchour","year":"2013","journal-title":"Retrovirology"},{"key":"10.1007\/s13311-015-0369-3_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002480","article-title":"Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy","volume":"8","author":"Tattermusch","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1007\/s13311-015-0369-3_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00063030-199810060-00003","article-title":"Adult T cell leukaemia: a review of established and new treatments","volume":"10","author":"Hermine","year":"1998","journal-title":"BioDrugs"},{"key":"10.1007\/s13311-015-0369-3_bib23","first-page":"147","article-title":"Immunopathogenesis and treatment of the myelopathy associated to the HTLV-1 virus","volume":"48","author":"Carod-Artal","year":"2009","journal-title":"Rev Neurol"},{"key":"10.1007\/s13311-015-0369-3_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/archneur.63.9.1318","article-title":"Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjogren-associated myelopathy","volume":"63","author":"Pot","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0369-3_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","article-title":"The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran","volume":"250","author":"Rafatpanah","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0369-3_bib26","first-page":"705","article-title":"The current and future approaches to the treatment of HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"70","author":"Yamano","year":"2012","journal-title":"Nihon Rinsho"},{"key":"10.1007\/s13311-015-0369-3_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ncl.2008.03.008","article-title":"Treatment of HTLV-1-associated myelopathy\/tropical spastic paraparesis: toward rational targeted therapy","volume":"26","author":"Oh","year":"2008","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-015-0369-3_bib28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","article-title":"Interferon-alpha is effective in HTLV-1-associated myelopathy: a multicenter, randomized, double-blind, controlled trial","volume":"46","author":"Izumo","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0369-3_bib29","first-page":"2712","article-title":"Evaluation of spasticity after stroke by using ultrasound to measure the muscle architecture parameters: a clinical study","volume":"7","author":"Yang","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1007\/s13311-015-0369-3_bib30","first-page":"685","article-title":"Validity and reliability of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form and its correlation with urodynamic findings","volume":"9","author":"Hajebrahimi","year":"2012","journal-title":"Urol J"},{"key":"10.1007\/s13311-015-0369-3_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/nau.20389","article-title":"Correlations between the ICIQ-SF score and urodynamic findings","volume":"26","author":"Seckiner","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1007\/s13311-015-0369-3_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/2193-1801-3-570","article-title":"Female sexual function after transobturator tape in women with urodynamic stress urinary incontinence","volume":"3","author":"Simsek","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1007\/s13311-015-0369-3_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.rbmo.2014.06.008","article-title":"Th17 cells and related cytokines in unexplained recurrent spontaneous miscarriage at the implantation window","volume":"29","author":"Saifi","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"10.1007\/s13311-015-0369-3_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jmv.23227","article-title":"Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy\/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease","volume":"84","author":"Furtado Mdos","year":"2012","journal-title":"J Med Virol"},{"key":"10.1007\/s13311-015-0369-3_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13550280152403272","article-title":"HTLV-1 proviral load correlates with progression of motor disability in HAM\/TSP: analysis of 239 HAM\/TSP patients including 64 patients followed up for 10 years","volume":"7","author":"Matsuzaki","year":"2001","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-015-0369-3_bib36","first-page":"268","article-title":"Human T-lymphotropic virus type 1 (HTLV-1) proviral load and clinical features in Iranian HAM\/TSP patients: comparison of HTLV-1 proviral load in HAM\/TSP patients","volume":"16","author":"Vakili","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2169\/internalmedicine1962.29.362","article-title":"The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy","volume":"29","author":"Nakamura","year":"1990","journal-title":"Jpn J Med"},{"key":"10.1007\/s13311-015-0369-3_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jneuroim.2004.02.007","article-title":"Th1\/Th2 balance and HTLV-1 proviral load in HAM\/TSP patients treated with interferon-alpha","volume":"151","author":"Feng","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0369-3_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0165-5728(03)00219-4","article-title":"Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM\/TSP","volume":"141","author":"Feng","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0369-3_bib40","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2007-04-085076","article-title":"Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy\/tropical spastic paraparesis patients","volume":"110","author":"Lezin","year":"2007","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0369-3_bib41","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1182\/blood-2010-02-270751","article-title":"Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors","volume":"116","author":"Afonso","year":"2010","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0369-3_bib42","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1182\/blood-2011-04-349910","article-title":"Safety of long-term treatment of HAM\/TSP patients with valproic acid","volume":"118","author":"Olindo","year":"2011","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0369-3_bib43","first-page":"213","article-title":"Effects of danazol on clinical improvement of patients with human T-cell lymphotropic virus type I associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): a placebo-controlled clinical trial","volume":"16","author":"Boostani","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1007\/s13311-015-0369-3_bib44","first-page":"259045","article-title":"Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy\/tropical spastic paraparesis: recent perspectives","volume":"2012","author":"Saito","year":"2012","journal-title":"Leukemia Res Treat"},{"issue":"Suppl. 1","key":"10.1007\/s13311-015-0369-3_bib45","first-page":"S91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases","volume":"83","author":"Gottlicher","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1007\/s13311-015-0369-3_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic Acid: second generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-015-0369-3_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdra.20748","article-title":"Human teratogens: update 2010","volume":"91","author":"Holmes","year":"2011","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1007\/s13311-015-0369-3_bib48","doi-asserted-by":"crossref","unstructured":"Lloyd KA. A scientific review: mechanisms of valproate-mediated teratogenesis. Bioscience Horizons 2013;6:hzt003.","DOI":"10.1093\/biohorizons\/hzt003"},{"key":"10.1007\/s13311-015-0369-3_bib49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1741-7015-11-183","article-title":"Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"11","author":"Kira","year":"2013","journal-title":"BMC Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0369-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0369-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:45:06Z","timestamp":1761806706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1878747923008206"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0369-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0369-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}